Bypassing Subtherapeutic Anticoagulation: DOACs vs. Warfarin After Bariatric Surgery

<p>Danielle Hess, Pharm.D. (<a href='https://twitter.com/dhess_09'>@dhess_09</a>) describes the potential effects of bariatric surgery on drug pharmacotherapy measures due to altered gastrointestinal anatomy, reviews literature pertaining to warfarin use after bariatric surgery and discusses safety and efficacy of direct-acting oral anticoagulants (DOACs) following bariatric surgery.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>